Sugi Predict

Sugi Predict / Compounds / SCHEMBL7183115

SCHEMBL7183115

SCHEMBL7183115

Cc1cccc(C)c1C(=O)[PH](=O)c1c(Br)ccc(C(=O)c2ccccc2)c1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MAPK14 Q16539 1/20 0.36
▸ MYC P01106 1/20 0.35
▸ POLB P06746 3/20 0.34
▸ MAPT P10636 2/20 0.34
▸ AKR1C3 P42330 3/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ KEAP1 Q14145 1/20 0.33
▸ NFE2L2 Q16236 1/20 0.33
▸ C5AR1 P21730 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189270 0.92 RORC (0.36) MEN1KMT2AMAPK14MYCMAPT
SCHEMBL7184420 0.90 MEN1 (0.39) MEN1KMT2APOLBMAPTAKR1C3
SCHEMBL7200655 0.87 MEN1 (0.37) MEN1KMT2APOLBMAPTNPC1
SCHEMBL7182229 0.86 MEN1 (0.37) MEN1KMT2AMAPK14POLBMAPT
SCHEMBL7176973 0.84 MAPT (0.44) MEN1KMT2AMAPK14MAPTNPC1
SCHEMBL7183550 0.82 NR1H2 (0.38) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL7182247 0.80 MAPT (0.40) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL7185476 0.79 LMNA (0.43) MEN1KMT2APOLBMAPTNPC1
SCHEMBL7174816 0.78 MAPT (0.37) KMT2AMAPK14MYCMAPTAKR1C3
SCHEMBL7178033 0.77 HTT (0.40) MEN1KMT2AMAPK14MYCPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885KMT2A 1586/4885MAPK14 952/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885KMT2A 956/4885MAPK14 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.